Jazz Pharmaceuticals (JAZZ)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
121.26
0.08 (0.07%)
At close: Jan 21, 2025, 3:59 PM
121.43
0.14%
After-hours Jan 21, 2025, 04:00 PM EST
Jazz Pharmaceuticals Revenue Breakdown
Quarter | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Defitelio/Defibrotide Revenue | 65.82M | 45.42M | 47.68M | 46.11M | 39.08M | 40.65M | 49.45M | 54.70M | 49.49M | 42.51M | 57.70M | 48.10M | 49.62M | 55.45M | 50.24M | 42.71M | 47.43M | 47.78M | 37.60M | 46.05M | 41.50M | 37.71M | 36.18M | 4.00M | 6.03M | 3.44M | 6.07M | 6.71M | 6.35M | 8.10M | 251.75M | 242.90M | 247.85M | 212.69M | 222.50M | 204.34M | 191.37M | 160.38M | 164.18M | 153.66M | 133.74M | 117.53M | 113.51M | 102.61M | 89.10M | 73.44M |
Defitelio/Defibrotide Revenue Growth | +44.91% | -4.73% | +3.40% | +17.99% | -3.87% | -17.79% | -9.59% | +10.52% | +16.41% | -26.33% | +19.98% | -3.07% | -10.52% | +10.38% | +17.62% | -9.95% | -0.73% | +27.06% | -18.35% | +10.98% | +10.04% | +4.24% | +803.52% | -33.58% | +75.49% | -43.37% | -9.61% | +5.73% | -21.65% | -96.78% | +3.64% | -2.00% | +16.53% | -4.41% | +8.89% | +6.78% | +19.32% | -2.32% | +6.84% | +14.90% | +13.80% | +3.53% | +10.62% | +15.17% | +21.32% | n/a |
Epidiolex/Epidyolex Revenue | 251.56M | 247.10M | 198.72M | 202.23M | 188.91M | 207.00M | 196.22M | 175.29M | 157.89M | 193.79M | 160.38M | 109.48M | 2.78M | 1.60M | 1.87M | 852.00K | 2.52M | 4.23M | 4.48M | 5.17M | 3.67M | 4.91M | 3.81M | 27.95M | 26.23M | 24.07M | 9.72M | 298.03M | 272.33M | 291.20M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Epidiolex/Epidyolex Revenue Growth | +1.80% | +24.35% | -1.74% | +7.05% | -8.74% | +5.49% | +11.94% | +11.02% | -18.52% | +20.83% | +46.49% | +3833.92% | +74.37% | -14.74% | +119.72% | -66.22% | -40.34% | -5.67% | -13.36% | +40.85% | -25.20% | +29.01% | -86.39% | +6.57% | +8.96% | +147.67% | -96.74% | +9.44% | -6.48% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Products Revenue | 2.23M | 2.70M | 3.57M | 3.42M | 3.43M | 3.07M | 1.00M | 1.63M | 943.00K | 1.03M | 3.34M | 2.64M | 603.53M | 661.30M | 596.95M | 26.57M | 32.72M | 31.52M | 29.58M | 31.36M | 28.94M | 25.62M | 21.04M | 356.01M | 316.78M | 312.48M | 303.87M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Products Revenue Growth | -17.38% | -24.43% | +4.48% | -0.50% | +11.97% | +206.39% | -38.66% | +73.06% | -8.45% | -69.20% | +26.62% | -99.56% | -8.74% | +10.78% | +2146.87% | -18.80% | +3.80% | +6.56% | -5.68% | +8.36% | +12.98% | +21.77% | -94.09% | +12.38% | +1.38% | +2.83% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Product And Services, Product Sales Net Of Deductions Revenue | 989.71M | 964.14M | 842.10M | 946.99M | 884.22M | 967.53M | 935.77M | 928.30M | 809.84M | 892.88M | 834.25M | 748.34M | 33.16M | 30.99M | 30.82M | 446.81M | 407.88M | 435.35M | 425.64M | 413.21M | 368.32M | 374.83M | 357.25M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Product And Services, Product Sales Net Of Deductions Revenue Growth | +2.65% | +14.49% | -11.08% | +7.10% | -8.61% | +3.39% | +0.80% | +14.63% | -9.30% | +7.03% | +11.48% | +2157.10% | +6.98% | +0.54% | -93.10% | +9.55% | -6.31% | +2.28% | +3.01% | +12.19% | -1.74% | +4.92% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sativex Revenue | 4.59M | 6.38M | 2.73M | 2.81M | 7.10M | 4.72M | 3.22M | 4.14M | 4.74M | 4.65M | 6.10M | 1.96M | 335.55M | 439.27M | 447.81M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sativex Revenue Growth | -28.15% | +133.38% | -2.53% | -60.47% | +50.35% | +46.61% | -22.26% | -12.65% | +2.00% | -23.75% | +210.91% | -99.42% | -23.61% | -1.91% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Oncology Revenue | 284.75M | 277.31M | 257.55M | 252.21M | 228.89M | 30.27M | 30.07M | 33.89M | 33.76M | 34.76M | 34.69M | 31.45M | 75.42M | 53.44M | 36.94M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Oncology Revenue Growth | +2.68% | +7.67% | +2.12% | +10.19% | +656.25% | +0.66% | -11.28% | +0.39% | -2.90% | +0.22% | +10.29% | -58.29% | +41.13% | +44.66% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Vyxeos Revenue | 34.31M | 43.01M | 32.02M | 34.06M | 36.70M | 247.50M | 256.04M | 269.42M | 247.50M | 288.76M | 307.33M | 334.18M | 54.33M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Vyxeos Revenue Growth | -20.22% | +34.32% | -5.97% | -7.20% | -85.17% | -3.34% | -4.97% | +8.86% | -14.29% | -6.04% | -8.03% | +515.05% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Xyrem Revenue | 58.11M | 62.18M | 64.23M | 159.77M | 178.13M | 281.38M | 255.94M | 235.03M | 186.08M | 182.65M | 153.06M | 124.16M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Xyrem Revenue Growth | -6.54% | -3.19% | -59.80% | -10.31% | -36.70% | +9.94% | +8.90% | +26.30% | +1.88% | +19.33% | +23.27% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Xywav Revenue | 388.47M | 368.47M | 315.30M | 326.56M | 277.76M | 71.97M | 70.32M | 68.28M | 59.34M | 64.84M | 71.71M | 55.92M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Xywav Revenue Growth | +5.43% | +16.86% | -3.45% | +17.57% | +285.95% | +2.34% | +2.98% | +15.08% | -8.48% | -9.59% | +28.23% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Zepzelca Revenue | 85.84M | 81.05M | 75.10M | 70.35M | 67.18M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Zepzelca Revenue Growth | +5.92% | +7.92% | +6.75% | +4.71% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
Quarter | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Europe Revenue | 239.64M | 230.16M | 175.21M | 150.20M | 125.91M | 122.79M | 106.15M | 103.61M | 126.72M | 61.84M | 38.59M | 6.22M |
Europe Revenue Growth | +4.12% | +31.36% | +16.65% | +19.29% | +2.54% | +15.68% | +2.44% | -18.23% | +104.90% | +60.26% | +520.02% | n/a |
Other Countries Revenue | 49.36M | 43.84M | 43.82M | 46.24M | 37.44M | 32.45M | 26.91M | 28.31M | 1.01B | 792.52M | n/a | n/a |
Other Countries Revenue Growth | +12.59% | +0.05% | -5.24% | +23.53% | +15.37% | +20.59% | -4.96% | -97.19% | +27.11% | n/a | n/a | n/a |
United States Revenue | 3.37B | 2.82B | 2.14B | 1.97B | 1.73B | 1.46B | 1.35B | 1.19B | n/a | n/a | n/a | n/a |
United States Revenue Growth | +19.51% | +31.51% | +9.12% | +13.76% | +18.05% | +8.01% | +13.58% | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
Quarter | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selling, General, and Administrative Revenue | 325.77M | 338.52M | 351.71M | 334.31M | 308.31M | 340.84M | 297.92M | 383.20M | 358.48M | 366.47M | 308.81M | 398.46M | 363.68M | 429.03M | 260.51M | 247.17M | 207.25M | 191.41M | 208.40M | 214.28M | 178.71M | 176.01M | 167.95M | 161.87M | 155.87M | 158.58M | 207.21M | 143.05M | 124.52M | 132.33M | 144.25M | 127.14M | 124.37M | 122.62M | 128.76M | 125.56M | 104.04M | 107.13M | 112.39M |
Selling, General, and Administrative Revenue Growth | -3.77% | -3.75% | +5.21% | +8.43% | -9.55% | +14.41% | -22.26% | +6.90% | -2.18% | +18.67% | -22.50% | +9.56% | -15.23% | +64.69% | +5.40% | +19.26% | +8.28% | -8.15% | -2.74% | +19.90% | +1.53% | +4.80% | +3.76% | +3.84% | -1.71% | -23.47% | +44.85% | +14.88% | -5.90% | -8.27% | +13.46% | +2.23% | +1.43% | -4.77% | +2.56% | +20.67% | -2.88% | -4.68% | n/a |
Research and Development Revenue | 199.92M | 220.73M | 222.85M | 216.61M | 234.40M | 209.24M | 189.41M | 172.56M | 148.87M | 139.05M | 129.98M | 155.44M | 141.04M | 132.70M | 76.57M | 91.70M | 78.65M | 78.92M | 86.11M | 97.38M | 79.86M | 62.38M | 60.10M | 56.66M | 51.16M | 56.13M | 62.67M | 66.00M | 47.36M | 40.16M | 44.93M | 44.16M | 47.80M | 39.09M | 31.25M | 29.45M | 50.78M | 27.83M | 27.18M |
Research and Development Revenue Growth | -9.43% | -0.95% | +2.88% | -7.59% | +12.03% | +10.47% | +9.77% | +15.91% | +7.06% | +6.97% | -16.38% | +10.22% | +6.29% | +73.29% | -16.50% | +16.60% | -0.35% | -8.34% | -11.58% | +21.95% | +28.01% | +3.79% | +6.09% | +10.74% | -8.86% | -10.43% | -5.04% | +39.34% | +17.94% | -10.62% | +1.74% | -7.61% | +22.27% | +25.08% | +6.10% | -42.00% | +82.46% | +2.40% | n/a |